Recently, the research team of Professor Xi Bo published a comment in the journal of Plos Med (JCR1 District, IF=11.60) and a meta-analysis in the journal of Sleep Med Rev (JCR1 District, IF=11.40). Professor Xi Bo is the first author and corresponding author in the first article and postdoctoral scholar Sun Jiahong and PhD candidate Ma Chuanwei are co-first authors. Professor Xi Bo is the corresponding author of the second article. The authors are all from the School of Public Health, Shandong University.
Given the international influence in the research field of tobacco use, Professor Xi Bo was invited by the editorial office of Plos Med to write a comment on the "change in the prevalence of tobacco use in urban and rural areas in China between 2007 and 2018" reported by Professor Zhou Maigeng from the Chinese Center for Disease Control and Prevention.
This comment indicated that a timely understanding of the change in the prevalence of tobacco use in China is of great significance for the government to formulate effective tobacco control policies. Although the tobacco smoking prevalence among Chinese adults decreased between 2007 and 2018, the decline rate was slow. To effectively control tobacco smoking in China, national or regional/provincial legislation and successful implementation of tobacco control policies are needed. Brazil is one example of successful implementation of tobacco control, mainly attributable to the strict national regulation on tobacco control and high adherence to the WHO Framework Convention on Tobacco Control. Policies and regulations enacted in China should include an increase in tobacco taxation, making harm warnings on cigarette packs more prominent or in combination with plain packaging, programs aimed at reducing the rate of smoking initiation, an increase in smoking cessation services, complete and up-to-date prohibition of tobacco sponsorship and advertising (especially for supervision of online tobacco marketing), and smoke-free home and public places.
The second research reviewed the association between daytime napping and obesity, hypertension, dyslipidemia, inflammation, diabetes, cardiovascular disease (CVD), and mortality. We found that long daytime napping (≥1 h/d) could increase the risk of CVD factors and mortality, whereas short daytime napping (<1 h/d) was not associated with most CVD risk factors and outcomes (no obvious benefits or harms). Dose-response analysis showed that for adults aged 60 years or older, daytime napping was significantly associated with an increased risk of diabetes, dyslipidemia, metabolic syndrome, and mortality in a dose-response manner (it is recommended that daytime napping should be controlled within 30 minutes among older adults). Indeed, current evidence can not conclude causal associations of daytime napping with CVD factors and outcomes. More large-scale population-based cohort studies and animal experiments are needed to validate the causal association.